Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518387

— · D

08fe26f9-0064-5403-9d37-5dff18fe4248

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.750
  • INTERFERON_GAMMA_RESPONSE+0.740
  • ALLOGRAFT_REJECTION+0.640
  • IL6_JAK_STAT3_SIGNALING+0.590
  • INFLAMMATORY_RESPONSE+0.530
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • COMPLEMENT+0.470
  • IL2_STAT5_SIGNALING+0.390
  • APOPTOSIS+0.350
  • KRAS_SIGNALING_UP+0.310

Top 10 suppressed

  • MYC_TARGETS_V1-0.340
  • ESTROGEN_RESPONSE_EARLY-0.320
  • GLYCOLYSIS-0.300
  • CHOLESTEROL_HOMEOSTASIS-0.280
  • ESTROGEN_RESPONSE_LATE-0.250
  • MYC_TARGETS_V2-0.230
  • OXIDATIVE_PHOSPHORYLATION-0.220
  • PEROXISOME-0.210
  • ANDROGEN_RESPONSE-0.190
  • MTORC1_SIGNALING-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518228
breast-umap@18
—D0.944
2BSR_02_0049_A5_S69
breast-umap@18
—D0.903
3SRR8518123
breast-umap@18
—D0.892
4SRR8518406
breast-umap@18
—D0.888
5SRR8613774
breast-umap@18
—D0.882
6SRR8518454
breast-umap@18
—D0.866
7ERR2208965
melanoma-umap@29
——0.862
8C3N-00247
lung-landscapes@6
—cohortMD20.854
9TCGA-75-5122-01A-01R-1755-07
lung-landscapes@6
—cohortA10.854
10SRR8613712
breast-umap@18
—D0.849

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.750Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.740Idelalisib— uncovered
ALLOGRAFT_REJECTION0.640Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.590Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.530Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
COMPLEMENT0.470Inavolisib— uncovered
IL2_STAT5_SIGNALING0.390Idelalisib— uncovered
APOPTOSIS0.350Idelalisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.260Inavolisib— uncovered
COAGULATION0.160Binimetinib— uncovered
P53_PATHWAY0.150Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.150Inavolisib— uncovered
HEME_METABOLISM0.110Temsirolimus— uncovered
APICAL_SURFACE0.090Temsirolimus— uncovered
G2M_CHECKPOINT0.090Inavolisib— uncovered
HYPOXIA0.080Idelalisib— uncovered
UV_RESPONSE_DN0.070Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.050Inavolisib— uncovered